TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26281607
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose group (112 patients) for acute diarrhea
Study: 26281607
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose group (113 patients) for acute diarrhea
Study: 26281607
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose group (56 patients) for chronic persistent diarrhea
Study: 26281607
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose group (55 patients) for chronic persistent diarrhea
Study: 22254076
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 140 µg/day
Study: 19929183
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity on Prescription (PAP) programme with exercise twice a week, education, and motivational counselling
Study: 19929183
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity on Prescription (PAP) programme
Study: 12717237
Drug: Rabbit antithymocyte
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit antithymocyte globulin (RATG) 1.5 mg/kg during the anhepatic phase followed by 1.5 mg/kg on posttransplant day 1
Study: 12717237
Drug: Methylprednisolone 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 1,000 mg followed by a 3-month steroid taper
Study: 8304789
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g dipyrone combined with a spasmolytic agent and 30 mg ketorolac tromethamine
Study: 2878600
Drug: Bevantolol 150
Normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevantolol 150 mg twice daily
Study: 28139557
Drug: Trimetazidine 35
Normalized name: trimetazidine 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 35 mg twice daily
Study: 28139557
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bisoprolol 1.25‐2.5 mg once daily and ivabradine 2.5‐7.5 mg twice daily
Study: 22212127
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine (Boostrix(®))
Study: 20159247
Drug: Intravenous montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous montelukast 7 mg
Study: 16278987
Drug: Phenylalanine-free essential
Normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylalanine-free essential amino acid tablets (AA tablets)
Study: 9951432
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 7.5 mg hydrocodone bitartrate with 200 mg ibuprofen
Study: 7790461
Drug: bismuth-antibiotic
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bismuth-antibiotic
Study: 30607985
Drug: Vestibular rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular rehabilitation therapy (VRT) plus placebo
Study: 15086356
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid plus vitamin B(6) (5 mg of folic acid plus 250 mg of vitamin B(6) daily)
Study: 8389710
Drug: T3 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 therapy
Study: 3318711
Drug: Penicillamine 20
Normalized name: Penicillamine
DrugBank: Penicillamine (DB00859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillamine 20 mg/kg/day
Study: 16357522
Drug: EGF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF vaccine (single or double dose, weekly for four weeks and monthly thereafter)
Study: 16357522
Drug: EGF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF vaccine (double dose)
Study: 16357522
Drug: EGF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF vaccine (good antibody response)
Study: 16357522
Drug: EGF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF vaccine (serum EGF decreased below 168 pg/ml)
Study: 16357522
Drug: EGF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF vaccine (overall treatment)
Study: 15273838
Drug: Dexamethasone administered
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administered before antibiotic therapy (Group I - 25 patients)
Study: 15273838
Drug: Dexamethasone administered
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administered concomitantly with antibiotics (Group II - 19 patients)
Study: 15273838
Drug: Dexamethasone administered
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administered after beginning antibiotic therapy (Group III - 14 patients)
Study: 809253
Drug: Intravenous TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TRH
Study: 8510087
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg and Hydrochlorothiazide 25 mg daily for 16 weeks
Study: 8510087
Drug: Captopril or
Normalized name: captopril Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril or Hydrochlorothiazide monotherapy for 4 weeks
Study: 2879981
Drug: Edmonston-Zagreb strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb strain by subcutaneous injection
Study: 2879981
Drug: Schwarz strain
Normalized name: measles virus vaccine live, attenuated Schwarz strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz strain by subcutaneous injection
Study: 31302339
Drug: SPX-101 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPX-101 (20 to 240 mg single doses and 10 to 120 mg BID for 14 days)
Study: 31302339
Drug: SPX-101 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPX-101 (10 mg-120 mg BID for 7 days)
Study: 26988864
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + 1.2% ATV gel
Study: 25610954
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of chocolate milk daily
Study: 19843656
Drug: Asenapine 5
Normalized name: asenapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 5 mg BID for 10 days followed by 10 mg BID for 6 days
Study: 19843656
Drug: Asenapine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 15 mg BID for 10 days followed by 20 mg BID for 6 days
Study: 19843656
Drug: Quetiapine 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 375 mg BID for 16 days
Study: 17074351
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen supplementation
Study: 14764210
Drug: Isobaric rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric rectal distension
Study: 8737557
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy with topical beta blockers
Study: 3595257
Drug: Mitoxantrone (M)
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone (M) mixed with poly(I).poly(C) (90 mg/m2)
Study: 3595257
Drug: Free Mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free Mitoxantrone (M) (30 mg/m2)
Study: 22717330
Drug: rHA 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHA 45 μg with Advax™ adjuvant
Study: 22717330
Drug: rHA 3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHA 3, 11 or 45 μg with or without adjuvant
Study: 18795960
Drug: TMC125 (etravirine)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TMC125 (etravirine) 800 mg bid
Study: 15657693
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids (prednisolone acetate 1% eye drops 5x/day for 6 months)
Study: 15657693
Drug: Combined systemic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined systemic (fluocortolone 1 mg/kg body weight per day tapered within 3 weeks) and topical steroids
Study: 12629101
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg T enanthate, im, weekly plus 125 micro g LNG, orally, daily (T+LNG)
Study: 12629101
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of T+LNG
Study: 11279969
Drug: Intranasal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal lidocaine 4%
Study: 11279969
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo 0.5 mL
Study: 1907362
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate (0.12 mg/kg)
Study: 1907362
Drug: Morphine-6-glucuronide (M6G:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-6-glucuronide (M6G: 0.03 mg/kg)
Study: 1907362
Drug: Morphine-6-glucuronide (M6G:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-6-glucuronide (M6G: 0.06 mg/kg)
Study: 6351658
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (prednisone, vincristine, and L-asparaginase)
Study: 24485633
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide (HDF, n=50, 20mg/h)
Study: 24485633
Drug: Low-dose furosemide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose furosemide and low-dose dopamine (LDFD, n=56, 5mg/h and 5 μg kg(‐1)min(‐1))
Study: 24485633
Drug: Low-dose furosemide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose furosemide (LDF, n=55, 5mg/h)
Study: 18034900
Drug: Order of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Order of administration (telephone interview first)
Study: 16136843
Drug: Caregiver training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver training program (N = 24) consisting of four sessions, including watching investigators administer the Texas Functional Living Scale and cueing patients to perform tasks.
Study: 12586806
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg atrasentan
Study: 7728983
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g of cooked Brussels sprouts per day
Study: 27932571
Drug: Esmolol, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol, 1 mg/kg before aortic cross‐clamping and 2 mg/kg with Custodiol® crystalloid cardioplegia
Study: 22952293
Drug: Intravesical bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical bacillus Calmette‐Guérin therapy
Study: 8895262
Drug: Dexamethasone 150
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 150 micrograms/kg up to a maximum dose of 8 mg, administered IV before surgery
Study: 6395464
Drug: Piperacillin 150
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin 150 mg/kg/day for 7.2 ± 2.75 days
Study: 6395464
Drug: Carbenicillin 200
Normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbenicillin 200 mg/kg/day for 7.5 ± 2.90 days
Study: 15864235
Drug: ezetimibe/simvastatin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin and atorvastatin
Study: 16540080
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive behaviour therapy (CBT) for 10 weeks
Study: 16540080
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behaviour therapy (CBT) for 10 weeks
Study: 12010934
Drug: Antiarrhythmic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic agents (Class IA)
Study: 12010934
Drug: Antiarrhythmic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic agents (Class IC)
Study: 12010934
Drug: Antiarrhythmic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic agents (Class III)
Study: 12010934
Drug: All drug
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drug classes
Study: 7641048
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium hyaluronate
Study: 30608463
Drug: TDP patch
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TDP patch
Study: 30608463
Drug: Lubricant gel
Normalized name: Surgilube Lubricant Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubricant gel patch (control)
Study: 26165012
Drug: Mild OSAHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild OSAHS Montelukast Treatment (MM) group - treated with leukotriene receptor antagonists (LTRAs)
Study: 26165012
Drug: Mild OSAHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild OSAHS Adenotonsillectomy Treatment (MAT) group - treated with adenotonsillectomy
Study: 26165012
Drug: Mild OSAHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild OSAHS Montelukast Treatment (MM) group
Study: 26165012
Drug: Severe OSAHS
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe OSAHS Montelukast Treatment (SM) group - treated with LTRAs
Study: 26165012
Drug: Severe OSAHS
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe OSAHS Adenotonsillectomy Treatment (SAT) group - treated with adenotonsillectomy
Study: 26165012
Drug: Mild OSAHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild OSAHS Adenotonsillectomy Treatment (MAT) group
Study: 26165012
Drug: Severe OSAHS
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe OSAHS Adenotonsillectomy Treatment (SAT) group
Study: 26165012
Drug: Severe OSAHS
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe OSAHS Montelukast Treatment (SM) group
Study: 12652333
Drug: Bilateral subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral subcutaneous hand injection of polyclonal human immunoglobulin G (HIgG) labelled with technetium‐99m
Study: 12652333
Drug: Bilateral subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral subcutaneous hand injection of polyclonal human immunoglobulin G (HIgG) labelled with indium‐111
Study: 9352953
Drug: Doxorubicin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin combination
Study: 7506170
Drug: nimesulide (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimesulide (100mg twice daily)
Study: 7506171
Drug: diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac (50 mg/kg twice daily)
Study: 3548627
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (2.4 g as a single intravenous dose)
Study: 27311846
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg flurbiprofen
Study: 18803888
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diclofenac sodium
Study: 20467920
Drug: high-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose dexamethasone plus thalidomide
Study: 20467920
Drug: high-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose dexamethasone plus lenalidomide (RD)
Study: 20467920
Drug: high-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose dexamethasone plus bortezomib (VD)
Study: 7328226
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment group
Study: 26988766
Drug: Blood insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood insulin levels at the start of EXER compared with CON and FAST
Study: 20345390
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (target hemoglobin 9.5-11.0 g/dL and 11.5-13.0 g/dL)
Study: 17030095
Drug: Pain-reducing ointment
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-reducing ointment (placebo)
Study: 17030095
Drug: Neutral ointment
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral ointment (control)
Study: 15204314
Drug: Combination low-fat/low-energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination low-fat/low-energy diet
Study: 10404809
Drug: Intranasal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal E2 (300 microg/day)
Study: 10404809
Drug: Intranasal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal E2 (100, 200, 300, and 400 microg/day)
Study: 10404809
Drug: Oral E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2 (1 and 2 mg/day)
Study: 2404636
Drug: Nicardipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (30 mg t.i.d.)
Study: 2404636
Drug: Nisoldipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (10 mg b.i.d.)
Study: 7043751
Drug: Sulfadoxine 20
Normalized name: Sulfadoxine
DrugBank: Sulfadoxine (DB01299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfadoxine 20 mg/kg and pyrimethamine 1.0 mg/kg (Group 1)
Study: 7043751
Drug: Sulfadoxine 30
Normalized name: Sulfadoxine
DrugBank: Sulfadoxine (DB01299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfadoxine 30 mg/kg and pyrimethamine 1.5 mg/kg (Group 2)
Study: 7043751
Drug: Quinine 10
Normalized name: quinine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 10 mg/kg 8 hourly for 5 days plus sulfadoxine 20 mg/kg and pyrimethamine 1.0 mg/kg (Group 3)
Study: 24321091
Drug: HIV‐1 DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV‐1 DNA vaccine at months 0, 1 and 3; HIV‐1 MVA vaccine at months 9 and 21
Study: 20638452
Drug: Intranasal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccine
Study: 20638452
Drug: Injectable vaccine
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable vaccine
Study: 20638452
Drug: Study interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study interventions (enhanced advertising, choice of vaccine type, and incentive)
Study: 20638452
Drug: Intentional vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intentional vaccine choice
Study: 10617952
Drug: High iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: High iron bioavailability diet (14.4 mg nonheme Fe/d, 1.8 mg heme Fe/d)
Study: 10617952
Drug: Low iron
Normalized name: Slow Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low iron bioavailability diet (15.3 mg nonheme Fe/d, 0.1 mg heme Fe/d)
Study: 10617952
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of high and low bioavailability diets
Study: 10617952
Drug: Low bioavailability
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low bioavailability diet
Study: 8654899
Drug: Nucleus cochlear
Normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleus cochlear implant users
Study: 3859954
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg PGE2 gel applied endocervically
Study: 3859954
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2 gel applied endocervically
Study: 3859954
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg PGE2 given pericervically through a portio adapter
Study: 18787893
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg BD
Study: 12848634
Drug: Valdecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib (40 mg b.d.)
Study: 1992102
Drug: Dapsone 200
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone 200 mg daily
Study: 6744646
Drug: Noradrenaline (alpha‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline (alpha‐1 adrenoceptor agonist)
Study: 6744646
Drug: Salbutamol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (beta 2‐adrenoceptor agonist)
Study: 30212253
Drug: Standard protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protein diet (1.1 g·kg‐1·day‐1, 39% fat)
Study: 30212253
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein diet (2.1 g·kg‐1·day‐1, 23% fat)
Study: 24906174
Drug: Lercanidipine 20
Normalized name: lercanidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 20 mg + Enalapril 20 mg
Study: 24906174
Drug: Lercanidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine (10 or 20 mg) or Enalapril (10 or 20 mg)